- Home
- GENK vs GDTC Comparison
GENK vs GDTC Comparison
Compare GENK & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- GDTC
- Stock Information
- Founded
- GENK 2011
- GDTC 2018
- Country
- GENK United States
- GDTC Singapore
- Employees
- GENK N/A
- GDTC 34
- Industry
- GENK Restaurants
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- GDTC Health Care
- Exchange
- GENK Nasdaq
- GDTC Nasdaq
- Market Cap
- GENK 20.4M
- GDTC 22.9M
- IPO Year
- GENK 2023
- GDTC 2023
- Fundamental
- Price
- GENK $3.14
- GDTC $1.97
- Analyst Decision
- GENK Strong Buy
- GDTC Buy
- Analyst Count
- GENK 2
- GDTC 1
- Target Price
- GENK $7.00
- GDTC $5.00
- AVG Volume (30 Days)
- GENK 73.2K
- GDTC 10.3K
- Earning Date
- GENK 08-06-2025
- GDTC 01-01-0001
- Dividend Yield
- GENK 3.81%
- GDTC N/A
- EPS Growth
- GENK N/A
- GDTC N/A
- EPS
- GENK N/A
- GDTC N/A
- Revenue
- GENK $216,137,000.00
- GDTC $368,838.00
- Revenue This Year
- GENK $12.35
- GDTC $5.37
- Revenue Next Year
- GENK $14.62
- GDTC N/A
- P/E Ratio
- GENK N/A
- GDTC N/A
- Revenue Growth
- GENK 10.67
- GDTC N/A
- 52 Week Low
- GENK $3.13
- GDTC $1.20
- 52 Week High
- GENK $10.33
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- GENK 37.18
- GDTC 56.13
- Support Level
- GENK $3.13
- GDTC $1.85
- Resistance Level
- GENK $3.39
- GDTC $2.07
- Average True Range (ATR)
- GENK 0.14
- GDTC 0.07
- MACD
- GENK 0.00
- GDTC 0.03
- Stochastic Oscillator
- GENK 10.58
- GDTC 67.48
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.